header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

General Orthopaedics

RAS/RAF/MEK/ERK PATHWAY IS ASSOCIATED WITH LUNG METASTASIS OF OSTEOSARCOMA IN AN ORTHOTOPIC MOUSE MODEL

Australian Orthopaedic Association and New Zealand Orthopaedic Association (AOA/NZOA) - Combined Annual Scientific Meeting



Abstract

To set up an osteosarcoma mouse model with spontaneous lung metastasis and to identify a marker of osteosarcoma metastasis and to inhibit the marker against the invasive ability of an osteosarcoma cell line.

A human osteosarcoma orthotopic mouse model was set up by injecting 143B human osteosarcoma cells into mouse tibia. Type I insulin-like growth factor receptor (IGF-1R) and its downstream signalling factors were measured in samples from the primary tumor and the lung secondaries by immunohistochemistry. Human Alu mRNA expression was tested using in situ hybridization assay. A Matrigel assay was used to assess cell invasion ability under the interference of a MEK/ERK pathway specific inhibitor, U0126.

All fifteen mice showed tumour mass at the left tibia and lung metastasis. Human Alu expression in the primary and secondary tumours confirmed human origin of the tumour cells. Total IGF-1R, MEK, Akt, p38 and phosphorylated MEK (p-MEK), but not p-Akt and p-p38, were positive in both local tumours and lung secondaries. Leiomyosarcoma controls expressed p-Akt and p-MEK, but not p-p38. The 143B cells treated with U0126 had significantly lower in vitro invasion ability compared with controls.

The IGF-1R-MEK signalling pathway, particularly Ras/Raf/MEK/ERK, may play an important role in osteosarcoma lung metastasis, and the targeting MEK/ERK by its specific inhibitor may have a potential use in the effective treatment of osteosarcoma.